NPM1 and acute myeloid leukemia: In our study, CEBPA and NPM1 mutations are not only predict favorable prognosis of pediatric CN-AML patients (CEBPA, P = 0.05, NPM1, P = 0.031), but also correlate with the risk score—lower risk score patients are more likely to have longer OS and DFS, and more often had these favorable mutations correlated with favorable outcomes.